Loading...
•
Jun 30, 2022
Scholar Rock Q2 2022 Earnings Report
Scholar Rock reported second quarter 2022 financial results and corporate updates.
Key Takeaways
Scholar Rock reported a net loss of $44.0 million for the second quarter of 2022. Enrollment continues to advance in the pivotal Phase 3 SAPPHIRE trial for apitegromab in SMA. The company's cash, cash equivalents, and marketable securities were approximately $371 million as of June 30, 2022.
Positive 24-month data from ongoing Phase 2 TOPAZ trial extension supports potential benefit of apitegromab for patients with Types 2 and 3 Spinal Muscular Atrophy (SMA).
Actively enrolling in pivotal Phase 3 SAPPHIRE clinical trial for apitegromab
Discovery pipeline advancements made for LTBP-TGFβ1 target to treat a wide range of fibrotic diseases
Significantly strengthened balance sheet with the completion of $205 million registered direct offering
Forward Guidance
Scholar Rock expects that its cash, cash equivalents, and marketable securities of approximately $371 million as of June 30, 2022, will fund the Company’s anticipated operating and capital expenditure requirements into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...